Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study

被引：2
|
作者：
Wang Feng [1 ]
Wang Junsheng [2 ]
Wu Tao [2 ]
Hong Yonggui [2 ]
Meng Xiangrui [1 ]
Ren Zhonghai [3 ]
Guo Yanzhen [4 ]
Yang Xiuli [5 ]
Shi Pei [5 ]
Yang Jiamei [6 ]
Fan Qingxia [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] AnYang Tumor Hosp, Anyang, Peoples R China
[3] Nanyang Cent Hosp, Nanyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 2, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Preoperative administration of camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): study protocol of a single-arm, open-label, phase II study
    Yang, Hang
    Guo, Yanan
    Zhao, Jia
    Zhang, Yan
    Jiao, Jia
    Mu, Teng
    Hou, Zhichao
    Huang, Qi
    Zhang, Guoqing
    Li, Xiangnan
    Li, Jindong
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4702 - 4710
  • [32] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [33] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
  • [34] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
    Tomita, Yoshihiko
    Tatsugami, Katsunori
    Nakaigawa, Noboru
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Kondoh, Chihiro Nakayama
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Tanaka, Shingo
    Kimura, Akiko
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
  • [35] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [36] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [37] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, Shengxiang
    He, Jianxing
    Fang, Yong
    Chen, Gongyan
    Ma, Zhiyong
    Chen, Jianhua
    Guo, Renhua
    Lin, Xiaoyan
    Yao, Yu
    Wu, Gang
    Wang, Quanren
    Zhou, Caicun
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [38] Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study
    Qu, Yanli
    Munire, Abulimiti
    Zhou, Ning
    Saifuding, Keyoumu
    Bulibu, Jilisihan
    Wang, Wei
    Tang, Xushan
    Li, Na
    Li, Junjie
    Wang, Peihong
    Tang, Yong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 1 - 11
  • [39] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [40] Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): A single-arm phase II study.
    Ye, Lulu
    Zhang, Lin
    Li, Rongrong
    Dou, Shengjin
    Jiang, Wen
    Zhu, Guopei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345